apolipoprotein B mRNA editing enzyme catalytic subunit 1
RGD ID:
2133
Description:
Enables several functions, including cytidine deaminase activity; enzyme activator activity; and ribonucleoprotein complex binding activity. Involved in several processes, including DNA cytosine deamination; RNA modification; and positive regulation of mRNA modification. Predicted to be part of apolipoprotein B mRNA editing enzyme complex. Predicted to be active in cytoplasm and nucleus. Used to study familial hyperlipidemia and liver benign neoplasm. Biomarker of colon cancer and obesity. Orthologous to human APOBEC1 (apolipoprotein B mRNA editing enzyme catalytic subunit 1); PARTICIPATES IN lipoprotein metabolic pathway; INTERACTS WITH 17alpha-ethynylestradiol; 17beta-estradiol; 17beta-estradiol 3-benzoate.
[Flame Retardants co-treated with pentabromodiphenyl ether co-treated with decabromobiphenyl ether co-treated with hexabromocyclododecane] results in increased expression of APOBEC1 mRNA
[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of APOBEC1 mRNA and [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of APOBEC1 mRNA
Apobec-1 transcription in rat colon cancer: decreased apobec-1 protein production through alterations in polysome distribution and mRNA translation associated with upstream AUGs.
Acute modulation of the extent of apoB mRNA editing and the relative rates of syntheses of apoB48 and apoB100 in cultured rat hepatocytes by osmotic and other stress stimuli.
Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming.
Plasma apolipoprotein B-48, hepatic apolipoprotein B mRNA editing and apolipoprotein B mRNA editing catalytic subunit-1 mRNA levels are altered in zinc-deficient rats.